Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR)-Reference-Cited by-同舟云学术

Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR)

Published:2012-07-15 Issue:5 Volume:36 Page:485-492
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Lanas A.¹,Goldstein J. L.²,Chan F. K. L.³,Wilcox C. M.⁴,Peura D. A.⁵,Li C.⁶,Sands G. H.⁶,Scheiman J. M.⁷

Affiliation:

1. CIBERehd. IIS Aragón; Universidad de Zaragoza; Zaragoza; Spain

2. Northshore University HealthSystem; Evanston; IL; USA

3. The Chinese University of Hong Kong; Hong Kong; China

4. University of Alabama; Birmingham; AL; USA

5. University of Virginia; Charlottesville; VA; USA

6. Pfizer Inc; New York; NY; USA

7. University of Michigan; Ann Arbor; MI; USA

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2012.05213.x/fullpdf

Reference36 articles.

1. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial;Chan;Lancet,2010

2. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents;Chan;Am J Gastroenterol,2008

3. A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract;Chan;J Rheumatol,2010

4. FDA Advisory Committee Briefing Document: Medical Officer's Gastroenterology Advisory Committee Briefing Document. Division of Anti-Inflammatory, Analgesic and Ophthalmologic Drug Products: HFD-550 www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_05_gi.pdf

5. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison;Cannon;Lancet,2006

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lafutidine Ameliorates Indomethacin-Induced Small Intestinal Damage in Rats by Modifying the Intestinal Mucosal Barrier, Inflammation, and Microbiota;Pharmacology;2023

2. Risk factors for small‐intestinal mucosal breaks beyond aspirin;Journal of Gastroenterology and Hepatology;2022-05-31

3. Role of proteinase-activated receptors 1 and 2 in nonsteroidal anti-inflammatory drug enteropathy;Pharmacological Reports;2020-06-24

4. Factors Associated With Adherence to Helicobacter pylori Testing During Hospitalization for Bleeding Peptic Ulcer Disease;Clinical Gastroenterology and Hepatology;2020-05

5. Effectiveness of acid suppressants and other mucoprotective agents in reducing the risk of occult gastrointestinal bleeding in nonsteroidal anti-inflammatory drug users;Scientific Reports;2019-08-12